Product Description: Orniplabin (SMTP-7) is a low-molecular-weight compound that enhances plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation. Orniplabin shows potential thrombolytic and anti-inflammatory effects. Orniplabin inhibits ROS[1][2].
Applications: COVID-19-immunoregulation
Formula: C51H68N2O10
References: [1]Shibata K, et al. A novel finding of a low-molecular-weight compound, SMTP-7, having thrombolytic and anti-inflammatory effects in cerebral infarction of mice. Naunyn Schmiedebergs Arch Pharmacol. 2010 Sep;382(3):245-53./[2]Shibata K, et al. Neuroprotective mechanisms of SMTP-7 in cerebral infarction model in mice. Naunyn Schmiedebergs Arch Pharmacol. 2011 Jul;384(1):103-8.
CAS Number: 733805-92-0
Molecular Weight: 869.09
Compound Purity: 95.0
Research Area: Inflammation/Immunology; Neurological Disease
Solubility: 10 mM in DMSO
Target: Reactive Oxygen Species
English
Deutsch
